Navigation Links
Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
Date:2/25/2008

SEOUL, South Korea, Feb. 25 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. announced today that its European licensee, Dr. Falk Pharma, has initiated a 200 patient, phase 2 proof of concept clinical study to investigate the use of udenafil, a long acting phosphodiesterase type 5 inhibitor, for portal hypertension, an unmet medical need. The multi-center, European study is designed to investigate the safety and efficacy of udenafil in a study population of patients with portal hypertension resulting from liver disease.

Udenafil represents a potential new pharmacotherapy in the growing and underserved portal hypertension market which is projected to be 6 million people (US, EU and Japan) by 2010. Portal hypertension is the build-up of pressure in the portal vein (the vein carrying blood from the spleen and digestive tract to the liver). A major complication related to portal hypertension is variceal bleeding, where increased pressure causes veins in the esophagus to rupture and bleed. These episodes are fatal in 30% of patients and reoccurring in 70% of survivors

The most common cause of portal hypertension is cirrhosis of the liver due to alcohol abuse or hepatitis. Cirrhosis from chronic liver disease ranks among the top 15 causes of death worldwide and is expected to increase over the next 20 years due to the prevalence of hepatitis C and hepatitis B, and an increase in non-alcoholic fatty liver disease in development countries.

An estimated 170 million people are infected with hepatitis C and 350 million with hepatitis B globally. It is estimated that up to 25% of those who are chronically infected with hepatitis will develop portal hypertension due to cirrhosis.

The epidemic of obesity in developed countries will lead to a greater incidence of non-alcoholic fatty liver disease (NAFLD), Type II diabetes and high cholesterol which can progress to non-alcoholic steatohepatitis (NASH) and lead to fibrosis and cirrhosis. It is expected t
'/>"/>

SOURCE Dong-A PharmTech Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
2. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
3. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
4. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
5. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
6. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
7. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
8. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
11. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... TAINAN, Taiwan, Nov. 19 /PRNewswire-Asia/ -- S...rmaceutical ingredients (APIs), announced that its...Safety Certification from,SafeBridge(R) Consultant...mpetency and proficiency in the safe handling of p...d applies to specific laboratories and,production ...
(Date:11/19/2009)...BBOTT PARK, Ill., Nov. 19 /PRNewswire-FirstCall/ -... ABT ) as one of its Most Admired Corporate Dealm... honored Abbott as its Most Admired Dealmaker in p... of acquisitions and divestitures since January 20...d its business portfolio with a focus on high-grow...
(Date:11/19/2009)... Part of International Internet Week of Action ,...swire/ -- The U.S. Food and Drug Administration to...al effort, called the International Internet Week ... involving medical products. ,, (Logo: http://..., During the effort, the FDA,s Office of Crimina...
Breaking Medicine Technology:ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Spectros Signs New International Distribution Deals 10418 1Spectros Signs New International Distribution Deals 10418 2Hospital Workers May Trigger Dangerous Outbreaks 59765 1Hospital Workers May Trigger Dangerous Outbreaks 59765 2Hospital Workers May Trigger Dangerous Outbreaks 59765 3Detecting the undetectable in prostate cancer screening 59761 1Detecting the undetectable in prostate cancer screening 59761 2Detecting the undetectable in prostate cancer screening 59761 3Detecting the undetectable in prostate cancer screening 59761 4
...l., Jan. 26 Data published online,today in Circul...ating the,XIENCE V(TM) Everolimus Eluting Coronary...ading XIENCE V outperforms the TAXUS(R) Express2(T...) in reducing major adverse,cardiac events (MACE) ...tients, XIENCE V demonstrated a 45 percent reducti...
...dentified, Versus Men , , NEW YORK, Jan. 26 Hype...isease that creates a thickening of the heart wall... death in children and young adults (<40). Mor...r one killer in women, the Hypertrophic Cardiomyop...in untreated for cardiac disease for decades, even...
Other Medicine Technology:Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent 2Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent 3Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent 4Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent 5Cardiac Disease in Women Remains Untreated for Decades 2
(Date:11/21/2009)...ive medical apparel company launches men,s lab coa... San Clemente, Calif. (PRWEB) November 21, 20... apparel, today announced the launch of its men,s ...leading international trade fair for the medical i...gurates its men,s collection with three varying la...
(Date:11/20/2009)... Closer to Understanding Brain Wiring and Diseases... -- Dr. Jeremy Schmahmann, Professor of Neurology ...assachusetts General Hospital in Boston, on Thursd...ch on the new field of study called "Connectivity"...r. Schmahmann is an award-winning leader in the fi...
(Date:11/20/2009)...s and Congressmen in Competitive Re-election Battl... , Washington, DC (Vocus)...ning for re-election next year in races deemed to ... come to regret voting for House Speaker Nancy Pel...ing Zogby International/ O’Leary Report pol...
(Date:11/20/2009)...ov. 20 Samuel Gladding ...what it means to be "happy" during the holidays. A...ty in family counseling and chair of the Departmen...g says research shows that it is the pressure to b...ssion during the holidays. ,, That,s why he,s c...
(Date:11/20/2009)... children with chronic kidney disease often fail t... visits increasing a child,s risk for serious hea...ins Children,s Center and other institutions. A re... of American Society of Nephrology. , Research...during regular doctor visits to readings obtained ...
Breaking Medicine News(10 mins):Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:Just 25% of Voters in Competitive 2010 Senate Races &#8220;Much More Likely&#8221; to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races &#8220;Much More Likely&#8221; to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:High blood pressure easy to miss in children with kidney disease 2
...edCommons announces integration of its,HealthURL A...n for Healthcare,Organizations. The EMC Open Syste...rovides a modular DICOM-compliant management platf...e. The,integration with the MedCommons appliance u...
...A with FDA in Early to Mid-2009 , , WARREN, N...m(R) technology and a drug delivery company specia...ucts, and Strativa Pharmaceuticals, the proprietar...ies for a thin film formulation of ondansetron. Th...
...ogic-Treated Psoriasis Patients Will Double by 201...es , , WALTHAM, Mass., Dec. 2 Decision Resou...sory firms for pharmaceutical and healthcare issue...ug market to more than double to nearly $5 billion...
...Dec. 2 Genoptix, Inc. (Nasdaq: GXDX ), a specia...d the Company,s participation at the RBC Capital M...e place at the Westin New York Hotel at Times Squa...rence on Wednesday, December 10, beginning at appr...
...if., Dec. 2 BioIQ , the leader in consumer-frien...re(R) , who provides services that include wellnes...mplex care management as well as case management o...e reporting tools as part of Alere,s Personal Heal...
... World Wide Dictation Service, one of the ...l transcription, and legal dictation transcription...ne.com , a non-profit organization geared to the b... NY (PRWEB) December 3, 2008 -- World Wide Dictati...
Other Medicine News:Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 2Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 3Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 2Health News:Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference 2Health News:BioIQ and Alere to Provide At-Home Biometric Screening Tests to Employees 2Health News:World Wide Dictation Service Teams up with TMATT for Local Thanksgiving Community Dinner 2
PHANTOM Absorbable Cannulated Interference Screws
AMO Vitrax (sodium hyaluronate) viscoelastic solution
CTF MEG 275
...for demonstration and training in: , binocular i...oscopy. , ,The Model Practice Eye is made of a s...eye size and shape and the flexibility and texture...mulate the optics of the human eye, thus permittin...
Medicine Products: